Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Benefits Of Grapefruit

National Falls Awareness Day - 23rd June 2009
The overall aim of National Falls Awareness Day, held on the 23rd June 2009 is to raise awareness of the increased risk of falling as people age. Many of the products in Mountway"s current extensive portfolio of independent living solutions can be used to aid with falls prevention.
generic viagra online
Economic Recession, Emerging Diseases Should Not Replace Efforts To Fight HIV/AIDS, IAS President Says
Concerns regarding the H1N1 flu strain or the current global economic recession should not take attention away from the long-term fight against HIV/AIDS, Julio Mantaner, head of the International AIDS Society, said recently, VOA News reports. Mantaner said global health issues need to be "put ... into the proper perspective," adding, "No doubt that ... whatever new flu or any other epidemic that may show up the day after tomorrow ... is something that we need to respond to. But it cannot be at the expense of a proven, established killer" like HIV/AIDS. He said that although it is important to remain vigilant in detecting emerging epidemics and infectious diseases, "we"re (doing) ourselves a very serious disservice" when res are taken away from combating HIV/AIDS and given to "the next new potential epidemic."Mantaner said that although it is "clear that we failed to meet original targets" in the global fight against HIV/AIDS, there has been an increase in the number of HIV-positive people in developing countries receiving antiretroviral treatments from about 500,000 in 2003 to more than three million by the end of 2007. In addition, he said that antiretrovirals are "saving lives of people" and "preserving the social network, the family structure ... that is so severely compromised by HIV and AIDS." Despite this progress, Mantaner said that "[w]e need to recognize more [people] are being infected every day by a factor of nearly two than the number of people accessing antiretroviral therapy."Mantaner urged members of the World Health Assembly -- who recently met in Geneva -- to honor HIV/AIDS commitments, noting that the gains in fighting the pandemic cannot be reversed. He said that he is concerned the global recession, worries over the H1N1 flu and other "competing needs or hypothetical epidemics" could lead to donor nations "losing their interest" in fighting HIV/AIDS. Mantaner said that he is disappointed with President Obama"s recent $63 billion, six-year proposed global health initiative, adding that it falls short of his campaign promises. He said that IAS is asking leaders from the Group of Eight industrialized nations to "refocus their efforts" and "meet their commitments." He warned that if the commitments are not met, "[h]istory is going to judge us very harshly," adding, "We"ve been distracted by the epidemic of the day without recognizing that we have a killer within our midst that we can control" (DeCapua, VOA News, 5/21).
News of the day
American Red Cross Bleeds Frontline Blood Drive Workers
Teamsters General President Hoffa called on the American Red Cross to support its frontline blood drive workers whose efforts help safeguard America"s blood supply. The Red Cross is currently pursuing a campaign against its frontline workers that would worsen working conditions, push down living standards, undermine workers" rights to representation, threaten safety standards and create a disposable work force.
Oncology

PLC Medical Systems To Demonstrate RenalGuard(R) At EuroPCR 2009

PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, announced that it will demonstrate its RenalGuard System(TM) at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 19-22, 2009, in Barcelona, Spain. More than 11,000 clinicians and professionals are expected to attend this event. In addition, RenalGuard(R) will be included as part of a live case transmission from Hospital Clinico San Carlos, Madrid, Spain during the meeting. The interventional cardiologists involved in the case plan to demonstrate how RenalGuard is used to help prevent Contrast-Induced Nephropathy (CIN) in a patient with impaired renal function undergoing a Percutaneous Coronary Intervention (PCI). "Following the spirit of EuroPCR, our commitment during these live cases is to provide valuable clinical education to EuroPCR attendees," stated Dr. Javier Escaned, Consultant Interventional Cardiologist, Hospital Clinico. "I consider that creating awareness of the problem of CIN and disseminating new information on how to prevent it are very important." Mark R. Tauscher, president and chief executive officer of PLC Systems, said, "We are very pleased to be presenting RenalGuard to this important audience, and especially pleased that Dr. Escaned will be demonstrating a live case illustrating how RenalGuard works and how it may benefit patients. CIN is a significant and growing concern worldwide, and we are very encouraged by the prospect that RenalGuard could remedy it." Currently, RenalGuard is the subject of an investigator-sponsored trial to study its efficacy in mitigating against CIN at the University of Milan-Centro Cardiologico Monzino (CCM). The trial is designed to provide an assessment of the potential benefits of induced diuresis with matched hydration therapy compared to standard overnight hydration, a prevalent method of treatment in the EU, in the prevention of CIN in patients undergoing cardiac catheterization procedures and percutaneous coronary interventions with baseline impairment in renal function. The CIN-prevention therapy of induced diuresis and matched hydration therapy will be provided using RenalGuard. PLC received the CE Mark Certificate for the RenalGuard System in December 2007, and concluded its pilot safety trial in the U.S. late in 2007. The company has received full approval from the FDA to commence a U.S. pivotal trial to study the effectiveness of RenalGuard in the prevention of CIN. In March 2008, PLC signed its first international distribution agreement for RenalGuard with Artech s.r.l., Cavezzo, Italy for distribution of its RenalGuard System into Italy, and in May 2009, PLC announced its second European distributor, IZASA Distribuciones Tecnicas S.A., headquartered in Barcelona, Spain, for the distribution of RenalGuard in Spain. About PLC Systems Inc. PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Massachusetts, PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. PLC"s newest product, RenalGuard, is approved for sale in the EU as a general fluid balancing device. This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, we may be unable to raise sufficient funds in the future to implement our business plan and/or commence our planned U.S. clinical trial for RenalGuard, the current clinical trial in Italy and the planned future U.S. clinical trial for RenalGuard as a safe and effective prevention device for contrast induced nephropathy may not be completed in a timely fashion, if at all, or, if these clinical trials are completed, they may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2008, and our other SEC reports. PLC Systems, PLC Medical Systems, PLC and CO2 Heart Laser, RenalGuard and RenalGuard System are trademarks of PLC Systems Inc. PLC Systems Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009